Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMolnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region
Global Molnupiravir market may register an impressive growth in the forecast period, 2023-2027, due to rising demands for the effective pharmaceuticals for the rising cases of COVID-19. High prevalence of the disease coupled with the viral variant complicating the conditions of the patients and thus leading to the severe conditions of the infection and causing death for population, drives the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster the market growth.
COVID-19
Rising Instances of COVID-19 Drives Market Growth
vaccinations
As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong from the United States itself. With the viral infection affecting such a large population in the country, the United States’ government had hastily authorized the administration of Molnupiravir to the patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side-effects in its early phase outs. Soon followed by the affordability of the drug as compared to other found at treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.
Investments & Advancement Wheel In Further Market Growth
Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease, drives the growth of the global Molnupiravir market in the upcoming five years. The consumers are eager to adapt to the more advanced, highly effective, and efficient drugs. If these drugs are affordable and are found at in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.
COVID-19 restricting drugs
Click here to download the sample
Market Segmentation
The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies.
Company Profile
Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Application · Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States, Mexico, Canada, China, India, Japan, Australia, South Korea, Vietnam, Philippines, Indonesia, Malaysia, Germany, France, United Kingdom, Spain, Italy, Denmark, Brazil, Argentina, Colombia, South Africa, UAE, Saudi Arabia, Kenya. |
| Key companies profiled | Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy